293 related articles for article (PubMed ID: 33302031)
1. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Yee K; Papayannidis C; Vey N; Dickinson MJ; Kelly KR; Assouline S; Kasner M; Seiter K; Drummond MW; Yoon SS; Lee JH; Blotner S; Jukofsky L; Pierceall WE; Zhi J; Simon S; Higgins B; Nichols G; Monnet A; Muehlbauer S; Ott M; Chen LC; Martinelli G
Leuk Res; 2021 Jan; 100():106489. PubMed ID: 33302031
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Uy GL; Assouline S; Young AM; Blotner S; Higgins B; Chen LC; Yee K
Invest New Drugs; 2020 Oct; 38(5):1430-1441. PubMed ID: 32020437
[TBL] [Abstract][Full Text] [Related]
3. MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.
Montesinos P; Beckermann BM; Catalani O; Esteve J; Gamel K; Konopleva MY; Martinelli G; Monnet A; Papayannidis C; Park A; Récher C; Rodríguez-Veiga R; Röllig C; Vey N; Wei AH; Yoon SS; Fenaux P
Future Oncol; 2020 May; 16(13):807-815. PubMed ID: 32167393
[TBL] [Abstract][Full Text] [Related]
4. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
Konopleva MY; Röllig C; Cavenagh J; Deeren D; Girshova L; Krauter J; Martinelli G; Montesinos P; Schäfer JA; Ottmann O; Petrini M; Pigneux A; Rambaldi A; Recher C; Rodriguez-Veiga R; Taussig D; Vey N; Yoon SS; Ott M; Muehlbauer S; Beckermann BM; Catalani O; Genevray M; Mundt K; Jamois C; Fenaux P; Wei AH
Blood Adv; 2022 Jul; 6(14):4147-4156. PubMed ID: 35413116
[TBL] [Abstract][Full Text] [Related]
5. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T; Hawtin R; Craig AR; Ravandi F; Maris MB; Stuart RK; Karp JE
Haematologica; 2015 Feb; 100(2):231-7. PubMed ID: 25381131
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.
Erba HP; Becker PS; Shami PJ; Grunwald MR; Flesher DL; Zhu M; Rasmussen E; Henary HA; Anderson AA; Wang ES
Blood Adv; 2019 Jul; 3(13):1939-1949. PubMed ID: 31253596
[TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
11. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
Corbali MO; Eskazan AE
Future Oncol; 2020 May; 16(14):887-889. PubMed ID: 32338053
[No Abstract] [Full Text] [Related]
12. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Sweet K; Komrokji R; Padron E; Cubitt CL; Turner JG; Zhou J; List AF; Sallman DA; Dawson JL; Sullivan DM; Chavez J; Shah BD; Lancet JE
Clin Cancer Res; 2020 Jan; 26(1):54-60. PubMed ID: 31636097
[TBL] [Abstract][Full Text] [Related]
13. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [
Pápai Z; Chen LC; Da Costa D; Blotner S; Vazvaei F; Gleave M; Jones R; Zhi J
Cancer Chemother Pharmacol; 2019 Jul; 84(1):93-103. PubMed ID: 31062077
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Daver NG; Dail M; Garcia JS; Jonas BA; Yee KWL; Kelly KR; Vey N; Assouline S; Roboz GJ; Paolini S; Pollyea DA; Tafuri A; Brandwein JM; Pigneux A; Powell BL; Fenaux P; Olin RL; Visani G; Martinelli G; Onishi M; Wang J; Huang W; Green C; Ott MG; Hong WJ; Konopleva MY; Andreeff M
Blood; 2023 Mar; 141(11):1265-1276. PubMed ID: 36265087
[TBL] [Abstract][Full Text] [Related]
15. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
[TBL] [Abstract][Full Text] [Related]
16. Oral idasanutlin in patients with polycythemia vera.
Mascarenhas J; Lu M; Kosiorek H; Virtgaym E; Xia L; Sandy L; Mesa R; Petersen B; Farnoud N; Najfeld V; Rampal R; Dueck A; Hoffman R
Blood; 2019 Aug; 134(6):525-533. PubMed ID: 31167802
[TBL] [Abstract][Full Text] [Related]
17. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Gojo I; Tan M; Fang HB; Sadowska M; Lapidus R; Baer MR; Carrier F; Beumer JH; Anyang BN; Srivastava RK; Espinoza-Delgado I; Ross DD
Clin Cancer Res; 2013 Apr; 19(7):1838-51. PubMed ID: 23403629
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Blotner S; Chen LC; Ferlini C; Zhi J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):597-607. PubMed ID: 29392451
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Reis B; Jukofsky L; Chen G; Martinelli G; Zhong H; So WV; Dickinson MJ; Drummond M; Assouline S; Hashemyan M; Theron M; Blotner S; Lee JH; Kasner M; Yoon SS; Rueger R; Seiter K; Middleton SA; Kelly KR; Vey N; Yee K; Nichols G; Chen LC; Pierceall WE
Haematologica; 2016 May; 101(5):e185-8. PubMed ID: 26869629
[No Abstract] [Full Text] [Related]
[Next] [New Search]
